Compounds > gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate
Page last updated: 2024-09-03

gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate and Central Nervous System Disease

gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate has been researched along with Central Nervous System Disease in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Berry, I; Brugières, P; de Schepper, AM; Degryse, HR; Gaston, A; Le Bras, F; Manelfe, C; Marsault, C; Parizel, PM; Wichmann, W1

Trials

1 trial(s) available for gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate and Central Nervous System Disease

ArticleYear
Randomised double blind trial of the safety and efficacy of two gadolinium complexes (Gd-DTPA and Gd-DOTA).
    Neuroradiology, 1994, Volume: 36, Issue:1

    Topics: Adult; Central Nervous System Diseases; Contrast Media; Double-Blind Method; Female; Gadolinium DTPA; Heterocyclic Compounds; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Organometallic Compounds; Pentetic Acid

1994